News

Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants

BETHESDA, Md., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing…

1 year ago

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

FREMONT, CA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical…

1 year ago

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth

Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of…

1 year ago

CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO

VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing…

1 year ago

Clearmind Medicine Announces 1-for-30 Reverse Share Split

Following the reverse share split, the Company will have 607,381 Ordinary Shares issued and outstanding Tel Aviv, Israel / Vancouver,…

1 year ago

Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…

1 year ago

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for…

1 year ago

NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on…

1 year ago

Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis

NX-13, a Novel, Oral, NLRX1 Agonist, was Observed to be Well Tolerated and Demonstrated Early Signs of Rapid Symptomatic Relief…

1 year ago

Stiffening of retinal blood vessels threatens vision in diabetes

Using atomic force microscopy, researchers at Doheny Eye Institute, an affiliate of UCLA, discovered retinal capillary stiffening in diabetic mice…

1 year ago